John Gutheil

5.5k total citations · 2 hit papers
40 papers, 4.2k citations indexed

About

John Gutheil is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, John Gutheil has authored 40 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Molecular Biology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in John Gutheil's work include Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Glycosylation and Glycoproteins Research (5 papers). John Gutheil is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer, Hypoxia, and Metabolism (6 papers) and Glycosylation and Glycoproteins Research (5 papers). John Gutheil collaborates with scholars based in United States, New Zealand and Taiwan. John Gutheil's co-authors include Debu Tripathy, Charles L. Vogel, Melody Cobleigh, Louis Fehrenbacher, Lyndsay N. Harris, William Novotny, Michael Burchmore, Steven Shak, Stanford J. Stewart and Dennis J. Slamon and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and Blood.

In The Last Decade

John Gutheil

39 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

2002 1.5k citations Charles L. Vogel, Melody Cobleigh et al. Journal of Clinical Oncology profile →
Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer

2001 507 citations Gerald Batist, Gopal Ramakrishnan et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by John Gutheil

Since Specialization

Citations

This map shows the geographic impact of John Gutheil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Gutheil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Gutheil more than expected).

Fields of papers citing papers by John Gutheil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Gutheil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Gutheil. The network helps show where John Gutheil may publish in the future.

Co-authorship network of co-authors of John Gutheil

This figure shows the co-authorship network connecting the top 25 collaborators of John Gutheil. A scholar is included among the top collaborators of John Gutheil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Gutheil. John Gutheil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.	Journal of Clinical Oncology	Yi‐Hsiang Huang, Kun‐Yun Yeh et al.	1
2	CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.	Journal of Clinical Oncology	Yi‐Hsiang Huang, Kun‐Yun Yeh et al.	1
3	Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer	Journal of Clinical Oncology	Charles L. Vogel, Melody Cobleigh et al.	16
4	CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study.	Journal of Clinical Oncology	Wu‐Chou Su, Li‐Yuan Bai et al.	3
5	MP43-02 CG0070, AN ONCOLYTIC ADENOVIRUS, FOR BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC): 18 MONTH FOLLOW-UP FROM A MULTICENTER PHASE II TRIAL	The Journal of Urology	Vignesh T. Packiam, Daniel A. Barocas et al.	12
6	A phase Ib/II study of oral nanatinostat (N) and valganciclovir (VG) in subjects with Epstein-Barr virus (EBV)-associated lymphomas.	Journal of Clinical Oncology	Pierluigi Porcu, Elizabeth Brém et al.	3
7	Abstract CT140: Phase I dose escalation study of 177Lu-HuMab-5B1 (MVT-1075) in combination with MVT-5873 as radioimmunotherapy (RIT) in subjects with relapsed / refractory pancreatic cancer or other CA19-9+ malignancies	Cancer Research	Christian Lohrmann, Joseph A. O’Donoghue et al.	5
8	An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results	Urologic Oncology Seminars and Original Investigations	Vignesh T. Packiam, Donald L. Lamm et al.	190
9	Phase I dose escalation study of CVM-1118, a novel anti-vascular mimicry agent, in patients with advanced cancers.	Journal of Clinical Oncology	Anthony W. Tolcher, Wu‐Chou Su et al.	2
10	Phase I/II Study of PR104, a Bioreductive Prodrug, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) Using Patient-Specific Adaptive Dose Selection	Blood	Marina Konopleva, Gautam Borthakur et al.	2
11	PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma	Cancer Chemotherapy and Pharmacology	Ghassan K. Abou‐Alfa, Stephen L. Chan et al.	24
12	A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors	Cancer Chemotherapy and Pharmacology	Michael B. Jameson, Danny Rischin et al.	68
13	Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer breakdown →	Journal of Clinical Oncology	Charles L. Vogel, Melody Cobleigh et al.	1508
14	First-Line Herceptin<sup>®</sup> Monotherapy in Metastatic Breast Cancer	Oncology	Charles L. Vogel, Melody Cobleigh et al.	145
15	Reduced Cardiotoxicity and Preserved Antitumor Efficacy of Liposome-Encapsulated Doxorubicin and Cyclophosphamide Compared With Conventional Doxorubicin and Cyclophosphamide in a Randomized, Multicenter Trial of Metastatic Breast Cancer breakdown →	Journal of Clinical Oncology	Gerald Batist, Gopal Ramakrishnan et al.	507
16	Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.	PubMed	Alison Stopeck, Evan M. Hersh et al.	90
17	Rapid and sensitive high-performance liquid chromatographic assay for novobiocin in human serum	Journal of Chromatography B Biomedical Sciences and Applications	Eleanor G. Zuhowski, John Gutheil et al.	5
18	Potential Applications of High-Dose Megestrol Acetate in Breast Cancer	Oncology	Jeffrey S. Abrams, John Gutheil et al.	1
19	RAS gene activation in acute myelogenous leukemia: Analysis by in vitro amplification and dna base sequence determination	Genes Chromosomes and Cancer	Shrikant Mane, Stephen J. Meltzer et al.	10
20	Immunoprecipitation of cell lysates with RAP-5 does not specifically detect ras oncogene product p21	Human Pathology	John Gutheil, Shrikant Mane et al.	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact